Have a feature idea you'd love to see implemented?
Let us know!
IMNM Immunome Inc
Price (delayed)
$9.42
Market cap
$587.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.11
Enterprise value
$434.76M
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are
Highlights
Immunome's quick ratio has surged by 55% YoY but it has decreased by 13% QoQ
IMNM's net income is down by 16% since the previous quarter
The equity has contracted by 15% from the previous quarter
Key stats
What are the main financial stats of IMNM
Market
Valuations
Earnings
Shares outstanding
62.42M
Market cap
$587.97M
Enterprise value
$434.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
55.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.92
Revenue
$10.13M
EBIT
-$305.35M
EBITDA
-$303.58M
Free cash flow
-$92.59M
Per share
Balance sheet
Liquidity
EPS
-$8.11
Free cash flow per share
-$1.54
Book value per share
$3.58
Revenue per share
$0.17
TBVPS
$4.27
Total assets
$256.9M
Total liabilities
$41.99M
Debt
$2.46M
Equity
$214.91M
Working capital
$204.51M
Debt to equity
0.01
Current ratio
6.17
Quick ratio
6.08
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
-2,997.2%
Gross margin
100%
Net margin
-3,014.6%
Operating margin
-3,134.4%
Return on assets
-119.6%
Return on equity
-139.7%
Return on invested capital
-589.6%
Return on capital employed
-140.5%
Return on sales
-3,014.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNM stock price
How has the Immunome stock price performed over time
Intraday
0.96%
1 week
-15.44%
1 month
-20.91%
1 year
18.49%
YTD
-11.96%
QTD
-35.57%
Financial performance
How have Immunome's revenue and profit performed over time
Revenue
$10.13M
Gross profit
$10.13M
Operating income
-$317.48M
Net income
-$305.35M
Gross margin
100%
Net margin
-3,014.6%
IMNM's net margin is down by 24% since the previous quarter
Immunome's operating margin has decreased by 24% from the previous quarter
Immunome's operating income has decreased by 17% QoQ
IMNM's net income is down by 16% since the previous quarter
Growth
What is Immunome's growth rate over time
Valuation
What is Immunome stock price valuation
P/E
N/A
P/B
2.63
P/S
55.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.92
IMNM's EPS is down by 5% QoQ
The price to book (P/B) is 46% lower than the 5-year quarterly average of 4.9 and 34% lower than the last 4 quarters average of 4.0
The equity has contracted by 15% from the previous quarter
IMNM's price to sales (P/S) is 17% lower than its last 4 quarters average of 67.4
The revenue fell by 6% QoQ
Efficiency
How efficient is Immunome business performance
The company's return on assets has shrunk by 181% YoY but it rose by 2.4% QoQ
The ROIC is up by 31% from the previous quarter
Immunome's ROE has increased by 27% YoY and by 12% from the previous quarter
IMNM's ROS is down by 24% QoQ
Dividends
What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNM.
Financial health
How did Immunome financials performed over time
The total assets has soared by 176% YoY but it has contracted by 13% from the previous quarter
The current ratio has soared by 56% YoY but it is down by 13% QoQ
IMNM's debt is 99% smaller than its equity
The equity has contracted by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.